REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.
2024年8月8日，马里兰州罗克维尔--REGENXBIO公司（纳斯达克：regenxbio）今天宣布，将于2024年8月15日周四参加H.C. Wainwright第四届年度在线眼科医疗大会。
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Panel: The Evolving Therapeutic Landscape of AMD
Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT
Location: Virtual
H.C. Wainwright第四届年度在线眼科医疗大会
专题讨论：AMD的不断发展的治疗手段
日期/时间：2024年8月15日周四美国东部时间上午9:00
地点：虚拟
A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
可在REGENXBIO网站的投资者部分访问该专题研讨会的实时网络直播，演示结束后约30天内可以查看其归档回放。
ABOUT REGENXBIO Inc.
关于REGENXBIO公司
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
REGENXBIO是一家领先的临床阶段生物技术公司，旨在通过基因疗法的治愈潜力改善人类生活。自2009年成立以来，REGENXBIO开创了AAV Therapeutics的发展，这是一种创新的基因疗法药物类别。REGENXBIO正在推进一系列用于视网膜和罕见疾病的AAV治疗，包括ABBV-RGX-314用于治疗激素性黄斑变性和糖尿病性视网膜病变，正在与AbbVie合作开发，RGX-202用于Duchenne的治疗和RGX-121用于MPS II的治疗。REGENXBIO的AAV Therapeutic平台已经治疗了成千上万的患者，包括诺华的ZOLGENSMA，用于治疗脊髓性肌萎缩症的儿童。作为一次性治疗，AAV Therapeutic具有改变数百万人的健康保健方式的潜力。有关更多信息，请访问 。
Contacts:
联系人：
Dana Cormack
Corporate Communications
[email protected]
达纳Cormack
企业通讯
[email protected]
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
[email protected]
投资者：
Chris Brinzey，ICR Westwicke
339-970-2843
[email protected]
SOURCE REGENXBIO Inc.
来源REGENXBIO公司。
